Novartis AG ADR (NVS)vsRallybio Corp (RLYB)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
RLYB
Rallybio Corp
$8.98
+1.13%
HEALTHCARE · Cap: $46.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6594072% more annual revenue ($56.58B vs $858,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RLYB
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for RLYB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 484.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -15.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RLYB
The strongest argument for RLYB centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 484.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : RLYB
The primary concerns for RLYB are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while RLYB is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
RLYB is growing revenue faster at 484.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rallybio Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Rallybio Corp is a clinical-stage biotechnology company dedicated to developing innovative therapies for rare diseases with a particular emphasis on unmet needs in immunology and hematology. The company features a promising pipeline of biologic drug candidates progressing through various clinical stages, supported by a highly experienced management team with extensive industry expertise. Strategic partnerships enhance Rallybio's ability to deliver transformative treatments, reinforcing its commitment to underserved therapeutic areas. With a clear focus on improving patient outcomes, Rallybio is strategically positioned to make a meaningful impact in the healthcare landscape while advancing toward commercial viability.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?